2018 SABCS Lobular Abstracts
 Share
The version of the browser you are using is no longer supported. Please upgrade to a supported browser.Dismiss

View only
 
 
ABCDEFGHIJKLMNOPQRSTUVWXYZ
1
ILC Abstracts presented at the San Antonio Breast Cancer Symposium 2018
2
3
[PD7-01] Bromodomain protein 3 is a novel therapeutic target in invasive lobular carcinoma
4
[PD7-02] Novel human cell line xenograft models of ER-positive metastatic invasive lobular breast carcinoma as pre-clinical platforms for validating candidate genetic drivers
5
[PD7-03] Investigating cortactin as a genetic driver of disease progression in invasive lobular carcinoma
6
[PD7-04] Metabolic syndrome increases risk of recurrence and impacts immune pathways in invasive lobular carcinoma
7
[PD7-05] Correlation of CDH1 alterations and aberrant E-cadherin expression in lobular carcinomas
8
[PD7-06] Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL
9
[P1-15-15] Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast
10
[P4-02-04] Tumor-infiltrating lymphocytes in invasive lobular breast cancer identify a poor prognostic sub-group
11
[P3-03-18] Invasive lobular carcinoma does not fit to axillary lymph node management according to NCCN guideline influenced by ACOSOG Z0011 criteria
12
[P3-06-03] Copy number analysis identifies ESR1 and MDM4 as drivers of progression in invasive lobular breast carcinoma
13
[P4-09-07] Higher risk of metachronous contralateral breast cancer in patients with invasive lobular breast cancer
14
[P4-14-12] Outcomes in hormone receptor positive, invasive lobular cancer in the era of endocrine monotherapy
15
[PD4-10] 18F-fluoroestradiol (FES) and 18F-fluorodeoxyglucose (FDG) PET imaging in staging extent of disease in metastatic lobular breast cancer
16
[GS1-06] Unraveling lobular breast cancer progression and endocrine resistance mechanisms through genomic and immune characterization of matched primary and metastatic samples
17
18
2018 LCIS Abstracts
19
[P5-18-01] Risk of contralateral breast cancer (CBC) in women with ductal carcinoma in situ (DCIS) with and without and synchronous lobular carcinoma in situ (LCIS)
20
[GS3-01] A randomized placebo controlled phase III trial of low dose tamoxifen for the prevention of recurrence in women with operated hormone sensitive breast ductal or lobular carcinoma in situ
21
22
Links provided courtesy of San Antonio Breast Cancer Symposium®” www.sabcs.org
23
View full poster and other research from SABCS2018 on www.sabcs.org under "past meetings".
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
Loading...